HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase II trial of bruceantin in metastatic breast carcinoma.

Abstract
A phase II evaluation of bruceantin was carried out in 15 patients with refractory metastatic breast cancer. All patients had received extensive prior therapy including adriamycin, cytoxan, 5-FU, methotrexate, and a vinca alkaloid. Except for two patients with stable disease, no complete or partial response was observed. Drug toxicity, mainly nonhematologic, was severe, with nausea, vomiting, mild hypotension, and fever being the most frequently encountered.
AuthorsC L Wiseman, H Y Yap, A Y Bedikian, G P Bodey, G R Blumenschein
JournalAmerican journal of clinical oncology (Am J Clin Oncol) Vol. 5 Issue 4 Pg. 389-91 (Aug 1982) ISSN: 0277-3732 [Print] United States
PMID7113961 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents, Phytogenic
  • Phenanthrenes
  • Quassins
  • Glaucarubin
  • bruceantin
Topics
  • Adult
  • Aged
  • Antineoplastic Agents, Phytogenic (adverse effects, therapeutic use)
  • Breast Neoplasms (drug therapy)
  • Drug Evaluation
  • Female
  • Glaucarubin (adverse effects, analogs & derivatives, therapeutic use)
  • Humans
  • Hypotension (chemically induced)
  • Leukocyte Count
  • Middle Aged
  • Nausea (chemically induced)
  • Neoplasm Metastasis
  • Phenanthrenes (therapeutic use)
  • Quassins
  • Vomiting (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: